Inflammatory Bowel Diseases (IBD): World Drug Industry and Market 2015-2025

世界の炎症性腸疾患(IBD)治療薬市場

◆タイトル:Inflammatory Bowel Diseases (IBD): World Drug Industry and Market 2015-2025
◆商品コード:VGAIN4120208
◆調査・発行会社:visiongain
◆発行日:2014年11月
◆ページ数:168
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single user licence(1名使用、1年)GBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Dept Licence(5名まで共有可、1年)GBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site Licence(全社内共有可、PDF制限なし)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、世界の炎症性腸疾患(IBD)治療薬市場について調査・分析し、イントロダクション、セグメント別市場分析、地域別市場分析、研究開発パイプライン、市場環境分析、専門家の見解、主要企業分析データなどをお届けいたします。

Treating Crohn’s disease and ulcerative colitis – how to find R&D trends, opportunities and revenue prospects
What’s the future of medicines for inflammatory bowel disease (IBD)? Those intestinal treatments retain high potential. Now you can explore sales forecasts and that industry’s research and development. See there how that large, profitable market expands.

Visiongain’s new investigation predicts those revenues to 2025 at overall world market, submarket, product and national level. Its purpose is to give data and analysis on therapies, assessing medical, technological and commercial potentials and opportunities.

Find where the most money and best prospects for business growth exist. Please read on to examine those colonic treatments, seeing how high that industry’s sales can go.

Forecasts and other analyses to help your gastrointestinal drug research, knowledge and influence
Avoid struggles to find that business information. Instead discover what’s happening in treating those lower digestive tract disorders. Now you can make your research, appraisals and decisions for the IBD market quicker and easier, also seeing where the money lies.

Besides revenue forecasting to 2025, our new report gives you commercial results, growth rates, market shares and discussions. There you get two interviews, 42 charts and 92 tables.

Discover how competition and technological advances shape that industry. Also benefit your reputation for knowledge. See what’s possible from now and how you can gain.

Forecasting of that world market and five therapeutic segments for those intestinal disorders
Our study predicts overall world revenue to 2025 for those anti-IBD drugs. There you also find individual revenue predictions to 2025 for five submarkets at world level:
• Biologics
• Aminosalicylates
• Antibiotics
• Corticosteroids
• Immunomodulators.

You investigate the most promising and lucrative parts of that industry. Gaining feel for opportunities, hear how those therapies can progress. You explore how, where, when and why rapid market expansion can occur.

For those medications, our analyses also investigate prominent brands.

Forecasts for 17 top products – discover sales potentials
How will leading drugs perform to 2025 at world level? Our study forecasts individual revenues of 17 prominent agents for those colonic disorders, including these agents:
• Humira (adalimumab)
• Remicade (infliximab)
• Asacol (mesalazine)
• Lialda (mesalamine)
• Tysabri (natalizumab)
• Cimzia (certolizumab pegol).

You also discover selling potentials of emerging therapies Simponi (golimumab), Uceris (budesonide) and Entyvio (vedolizumab). There you see prospects for monoclonal antibodies – leading biological drugs.

Our study shows how high sales can go, to 2025, revealing medicines and years with highest predicted growth and revenues. Treating large-intestine disease holds much commercial potential. And you find what the future holds for treating inflamed bowel.

You also discover geographical revenue predictions.

Healthcare in national markets – what outlooks for selling those pharmaceuticals?
Our study shows you individual revenue forecasting to 2025 for 11 countries:
• United States (US)
• Japan
• Germany, France, UK, Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC nations).

There you find countries with highest IBD revenues, demand and potential sales. Investigate progress, needs and opportunities, seeing how you can gain.

And how do changes, challenges and technological advances affect that biopharma industry and market?

Forces, events and issues – developments influencing those treatments and their producers
That new analysis explains policies, trends and R&D shaping that industry and market, including these influences:
• Aetiology, disease incidence, prevalence and diagnosis
• Prospects for developing interleukin (IL), cell-adhesion molecule (CAM), JAK and TNF inhibitors – discovering and testing molecular targets
• Progress in stem cells and toll-like receptor agonists – emerging therapy
• Monoclonal antibodies (mAbs) and biosimilars (follow-on protein products) – see their prospects for changing that gastrointestinal (GI) sector
• Delivery systems for agents treating those medical conditions – advances in supporting technology.

In 2014 there exist 37 promising new agents with various mechanisms of action, and nine proposed biosimilar molecules in clinical trials for Crohn’s disease and ulcerative colitis.

Our study gives you feel for that market – its progress and potential. Also you discover what stimulates and restrains that industry. That way you’re less likely to fall behind.

Treatments for inflamed lower intestine – prominent companies and 2018 market value
What happens next? From 2015 IBD medicines hold great potential for investments, technologies, medical advances and sales. Our new report predicts the world market for those products will reach $10.2bn in 2018, with strong revenue growth from 2014.

That work also explores activities, results and potentials of top companies, especially these firms:
• AbbVie
• Janssen Biotech
• Actavis
• Shire Pharmaceuticals.

【レポートの目次】

1. Report Overview
1.1 World IBD Drugs Market: Overview of Findings
1.2 Why You Should Read This Report
1.3 How That Study Delivers Value
1.4 Main Questions Covered in That Analysis
1.5 Who is the Investigation For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Titles
1.9 About Visiongain

2. Introduction to the Inflammatory Bowel Disease Market
2.1 What is Inflammatory Bowel Disease (IBD)?
2.2 Classification of IBD
2.3 Symptoms and Diagnosis of IBD
2.4 Multifactorial Causes of IBD
2.5 How Common is IBD?
2.6 What Are the Treatment Options for IBD?
2.6.1 Aminosalicylates – The Most Common Therapy
2.6.2 Antibiotics – Will There Be Any Supporting Evidence Soon?
2.6.3 Corticosteroids – Uptake from Uceris?
2.6.4 Immunomodulators – Slow to Act?
2.6.5 Monoclonal Antibodies – Not Cost-effective?
2.7 Treatment Goals for IBD – Treat-to-Target Approach?
2.8 Treatment Algorithm – is Top-Down Approach the Future Direction?

3. The World Inflammatory Bowel Disease Market, 2014-2025
3.1 The Inflammatory Bowel Disease Market in 2013 and 2014
3.2 Forecast 2014-2025: Changes Expected?
3.3 Biologic Therapies Forecast 2014-2025 – The Future of Pharma
3.4 Aminosalicylates Forecast 2014-2025: The Work Horse of IBD Market
3.5 Antibiotics Forecast 2014-2025: Scientific Research Important
3.6 Corticosteroids Forecast 2014-2025: Will Uceris Save the Day?
3.7 Immunomodulators Forecast 2014-2025 – Will It Remain Insignificant?

4. Market Prospects for Leading IBD Drugs, 2014-2025
4.1 Humira (AbbVie) – Will It Stand the Wave of Biosimilars?
4.1.1 Humira: Forecast and Analysis, 2014-2025
4.2 Remicade (Janssen Biotech) – Rise and Fall with Humira?
4.2.1 Remicade: Forecast and Analysis, 2014-2025
4.3 Asacol (Actavis) – Will It Regain Its Revenue?
4.3.1 Asacol: Forecast and Analysis, 2014-2025
4.4 Pentasa (Shire) – When Will a Generic Substitute Arrive?
4.4.1 Pentasa: Forecast and Analysis, 2014-2025
4.5 Lialda (Shire) – Will Improved Compliance Increase Revenue?
4.5.1 Lialda: Forecast and Analysis, 2014-2025
4.6 Tysabri (Perrigo) – How Dependable its Prospects?
4.6.1 Tysabri: Forecast and Analysis, 2014-2025
4.7 Xifaxan (Salix Pharmaceuticals) – Growing Stronger?
4.7.1 Xifaxan: Forecast and Analysis, 2014-2025
4.8 Cimzia (UCB) – How Will it Fare Against Biosimilars?
4.8.1 Cimzia: Forecast and Analysis, 2014-2025
4.9 Entocort (AstraZeneca) – A Slow and Steady Decline?
4.9.1 Entocort: Forecast and Analysis, 2014-2025
4.10 Neoral (Novartis) – Immunosuppressant
4.10.1 Neoral: Forecast and Analysis, 2014-2025
4.11 Medrol (Pfizer Inc.) – Another Leading Steroid
4.11.1 Medrol: Forecast and Analysis, 2014-2025
4.12 Canasa (Actavis) – A Slow Decline?
4.12.1 Canasa/Salofalk: Forecast and Analysis, 2014-2025
4.13 Apriso (Salix Pharmaceuticals) – Challenger to Asacol?
4.13.1 Apriso: Forecast and Analysis, 2014-2025
4.14 Azulfidine (Pfizer) – Established Product
4.14.1 Azulfidine: Forecast and Analysis, 2014-2025
4.15 Entyvio (Takeda Pharmaceuticals) – a Future Star Product?
4.15.1 Entyvio: Forecast and Analysis, 2014-2025
4.16 Simponi (Janssen Biotech) – Another Rising Star for the Market?
4.16.1 Simponi: Forecast and Analysis, 2014-2025
4.17 Uceris (Salix) – Corticosteroid for Maintenance Therapy?
4.17.1 Uceris: Forecast and Analysis, 2014-2025

5. Leading National Markets: Sales Outlooks, 2014-2025
5.1 IBD Drugs – Leading National Markets 2013
5.2 The US IBD Drug Market, 2014-2025 – The World Leader
5.3 The Japanese IBD Drug Market, 2014-2025 – Growing Significantly?
5.4 The EU-5 IBD Drug Market, 2014-2025 – Still Growing Together
5.4.1 The German IBD Drug Market, 2014-2025
5.4.2 The French IBD Drug Market, 2014-2025
5.4.3 The UK IBD Drug Market, 2014-2025
5.4.4 The Spanish IBD Drug Market, 2014-2025
5.4.5 The Italian IBD Drug Market, 2014-2025
5.5 IBD Drug Markets in BRIC Countries – How Fast Will They Grow?
5.5.1 The Brazilian IBD Drug Market, 2014-2025
5.5.2 The Russian IBD Drug Market, 2014-2025
5.5.3 The Indian Drug Market, 2014-2025
5.5.4 The Chinese IBD Drug Market, 2014-2025

6. The R&D Pipeline for Inflammatory Bowel Disease, 2014
6.1 Interleukin (IL) Inhibitors – One of the Main Areas of Innovation
6.1.1 CyCol (Sigmoid Pharma)
6.1.2 PF-04236921 (Pfizer)
6.1.3 QAX 576 (Novartis)
6.1.4 TNF Kinoid (Neovacs)
6.1.5 Vidofludimus (4SC) – Suspended
6.1.6 Stelara (Ustekinumab, CNTO 1275, Janssen Biotech)
6.2 Cell-Adhesion Molecule (CAM) Inhibitors – A Promising Avenue
6.2.1 AJG 511 (Ajinomoto Pharmaceutical Co.)
6.2.2 AJM 300 (Ajinomoto Pharmaceuticals)
6.2.3 MEDI 7183/AMG 181 (AstraZeneca & Amgen)
6.2.4 Etrolizumab (Roche)
6.2.5 PF-00547659 (Pfizer)
6.2.6 Alicaforsen (ISIS 2302, Atlantic Healthcare)
6.2.7 MEDI-2070/AMG 139 (AstraZeneca & Amgen)
6.2.8 Entyvio (Vedolizumab, Takeda)
6.3 TNF Inhibitors – a Specific Target
6.3.1 AVX-470 (Avaxia Biologics)
6.3.2 Ozoralizumab (ALX-0061, Ablynx)
6.4 Stem Cell Therapies – Basis for a Cure?
6.4.1 Ovasave (TxCell)
6.4.2 MultiStem (Athersys and Pfizer)
6.4.3 Prochymal (Remestemcel-L, Osiris Therapeutics)
6.4.4 Cx601 (TiGenix
6.5 JAK Inhibitors – New Target Pathway
6.5.1 JNJ-54781532 (Janssen)
6.5.2 Xeljanz, (Tofacitinib, CP-690550, Pfizer)
6.6 Toll-like Receptor Agonists
6.6.1 BL-7040 (BioLineRX)
6.6.2 Kappaproct (InDex Pharmaceuticals)
6.7 Other Classes of Agent
6.7.1 Trichuris suis ova (CNDO-201, Coronado Biosciences)
6.7.2 GLPG0974 (Galapagos)
6.7.3 RPC1063 (Receptos)
6.7.4 SGX203 (Soligenix)
6.7.5 Mongersen (GED-0301, Celgene)
6.7.6 Tetomilast (OPC-6535, Otsuka)
6.7.7 Laquinimod (Active Biotech)
6.7.8 RHB-104 (RedHill Biopharma)
6.7.9 TRK 170 (Toray Industries)
6.8 Biosimilars Candidates – Promising Copies of Leading Biologics?
6.8.1 Possibility of Adalimumab Biosimilars
6.8.2 Possibility of Infliximab Biosimilars

7. Drivers and Restraints in the Inflammatory Bowel Disease Drug Industry and Market, 2015
7.1 SWOT and STEP Analysis of the IBD Market
7.2 What Factors Will Stimulate the IBD Market?
7.2.1 Increasing Disease Incidence
7.2.2 Better Diagnosis – Early Referrals
7.2.3 Delivery Systems
7.2.4 Biological Drugs
7.2.5 Socioeconomic Costs of IBD
7.3 What Factors Will Restrain the Market?
7.3.1 Lack of Understanding of Disease Aetiology
7.3.2 Compliance
7.3.3 Limits of Biologics
7.3.4 The Possible Development of Alternative Treatments
7.3.5 Surgery – Treatment for Recalcitrant IBD
7.3.6 Health Care Cost Containment

8. Leading Companies in the IBD Market, 2014
8.1 The Largest Companies by Revenue
8.1.1 AbbVie – Current Leader and Continually Expanding
8.1.2 Janssen Biotech – Contender for Future Leader of that Market
8.1.3 Actavis – New Comer in the Top Four
8.1.4 Shire Pharmaceuticals – Products and R&D

9. Research Interviews
9.1 Dr Karine Kleinhaus, Divisional Vice President, North America, Pluristem Therapeutics Inc.
9.1.1 On Pluristem Therapeutics Inc.
9.1.2 On PLX Cells
9.1.3 MoA of PLX Cells and What They are Indicated For
9.1.4 Clinical Trial for IBD Indication
9.1.5 Prospects of PLX Cells as a Treatment Option for IBD
9.1.6 On NIH’s Initiation of the Human Placental Project
9.1.7 Cell Therapy and its Place in Biopharma Development
9.1.8 Bridging Clinical Trial and Clinical Outcome
9.1.9 On Pluristem’s Partnerships
9.2 Dr Qamar ul Arfin, Gastroenterologist, Aga Khan University Hospital, Karachi, Pakistan
9.2.1 On Antibiotics in Treating IBD
9.2.2 On the Emergence of Biologic Therapies
9.2.3 On IBD in the Pakistani Context
9.2.4 On Preventative Measures that Can Be Taken

10. Conclusions of the Study
10.1 IBD Market to Expand from 2014 to 2025
10.2 Aminosalicylates and Other Non-Biologic Treatments
10.3 Biological Treatments
10.4 Improvements Needed in IBD Therapy
10.5 Future IBD Treatments: R&D Efforts Look Promising
10.6 The IBD Sector: Looking to the Future with Confidence

List of Tables
Table 1.1 Regional and National IBD Drug Markets: Sizes ($m), Annual Growth (%), CAGR (%), 2014-2019
Table 1.2 Regional and National IBD Drug Markets: Sizes ($m), Annual Growth (%), CAGR (%), 2020-2025
Table 2.1 Differentiating Crohn’s Disease and Ulcerative Colitis
Table 2.2 Worldwide Prevalence Rates for IBD, 2014
Table 2.3 Worldwide Incidence Rates for IBD, 2014
Table 2.4 Geographical Variations in the Incidence of IBD, 2010
Table 2.5 Other Drug Types Used to Treat IBD, 2014
Table 2.6 Treatment Protocol for IBD, 2014
Table 3.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2013 and 2014
Table 3.2 Global IBD Drug Market Forecast ($m), 2014-2025
Table 3.3 Global IBD Drug Forecast by Drug Category ($m) 2014-2025
Table 3.4 Global IBD Drug Market Drivers and Restraints 2014-2025
Table 3.5 Global Biologics Forecast for IBD Market ($m), 2014-2025
Table 3.6 Global Biologic Therapies Drivers and Restraints, 2014-2025
Table 3.7 Global Aminosalicylates Forecast for IBD Market ($m), 2014-2025
Table 3.8 Global Aminosalicylates Drivers and Restraints, 2014-2025
Table 3.9 Global Antibiotics Forecast for IBD Market ($m), 2014-2025
Table 3.10 Global Antibiotics Drivers and Restraints, 2014-2025
Table 3.11 Global Corticosteroids Forecast for IBD Market ($m), 2014-2025
Table 3.12 Global Corticosteroids Drivers and Restraints, 2014-2025
Table 3.13 Global Immunomodulators Forecast for IBD Market ($m), 2014-2025
Table 3.14 Global Immunomodulators Drivers and Restraints, 2014-2025
Table 4.1 Leading IBD Treatments by Revenue ($m), 2013
Table 4.2 Leading IBD Medicines: Revenue Forecasts ($m), 2014-2019
Table 4.3 Leading IBD Medicines: Revenue Forecasts ($m), 2020-2025
Table 4.4 World Humira Revenue Forecast ($m), 2014-2025
Table 4.5 Drivers and Restraints for Humira, 2014-2025
Table 4.6 World Remicade Forecast ($m), 2014-2025
Table 4.7 Drivers and Restraints for Remicade, 2014-2025
Table 4.8 World Asacol Forecast ($m), 2014-2025
Table 4.9 Drivers and Restraints for Asacol, 2014-2025
Table 4.10 World Pentasa Forecast ($m), 2014-2025
Table 4.11 Drivers and Restraints for Pentasa, 2014-2025
Table 4.12 World Lialda Forecast ($m), 2014-2025
Table 4.13 Drivers and Restraints for Lialda, 2014-2025
Table 4.14 World Tysabri Forecast ($m), 2014-2025
Table 4.15 Drivers and Restraints for Tysabri, 2014-2025
Table 4.16 World Xifaxan Forecast ($m), 2014-2025
Table 4.17 Drivers and Restraints for Xifaxan, 2014-2025
Table 4.18 World Cimzia Forecast ($m), 2014-2025
Table 4.19 Drivers and Restraints for Cimzia, 2014-2025
Table 4.20 World Entocort Forecast ($m), 2014-2025
Table 4.21 Drivers and Restraints for Entocort, 2014-2025
Table 4.22 World Neoral Forecast ($m), 2014-2025
Table 4.23 Drivers and Restraints for Neoral, 2014-2025
Table 4.24 World Medrol Forecast ($m), 2014-2025
Table 4.25 Drivers and Restraints for Medrol, 2014-2025
Table 4.26 World Canasa Forecast ($m), 2014-2025
Table 4.27 Drivers and Restraints for Canasa, 2014-2025
Table 4.28 World Apriso Forecast ($m), 2014-2025
Table 4.29 Drivers and Restraints for Apriso, 2014-2025
Table 4.30 World Azulfidine Forecast ($m), 2014-2025
Table 4.31 Drivers and Restraints for Azulfidine, 2014-2025
Table 4.32 World Entyvio Forecast ($m), 2014-2025
Table 4.33 Drivers and Restraints for Entyvio, 2014-2025
Table 4.34 World Simponi Forecast ($m), 2014-2025
Table 4.35 Drivers and Restraints for Simponi, 2014-2025
Table 4.36 World Uceris Forecast ($m), 2014-2025
Table 4.37 Drivers and Restraints for Uceris, 2014-2025
Table 5.1 IBD Drug Revenues ($m) by Leading Country, 2013
Table 5.2 Global IBD Drug Market Forecasts ($m) by Leading Country, 2014-2019
Table 5.3 Global IBD Drug Market Forecasts ($m) by Leading Country, 2020-2025
Table 5.4 US IBD Drug Market Forecast ($m), 2014-2025
Table 5.5 Japanese IBD Drug Market Forecast ($m), 2014-2025
Table 5.6 EU5 IBD Drug Market Forecasts ($m), 2014-2019
Table 5.7 EU5 IBD Drug Market Forecasts ($m), 2020-2025
Table 5.8 German IBD Drug Market Forecast ($m), 2014-2025
Table 5.9 French IBD Drug Market Forecast ($m), 2014-2025
Table 5.10 UK IBD Drug Market Forecast ($m), 2014-2025
Table 5.11 Spanish IBD Drug Market Forecast ($m), 2014-2025
Table 5.12 Italian IBD Drug Market Forecast ($m), 2014-2025
Table 5.13 BRIC IBD Drug Market Forecasts ($m), 2014-2019
Table 5.14 BRIC IBD Drug Market Forecasts ($m), 2020-2025
Table 5.15 Brazilian IBD Drug Market Forecast ($m), 2014-2025
Table 5.16 Russian IBD Drug Market Forecast ($m), 2014-2025
Table 5.17 Indian IBD Drug Market Forecast ($m), 2014-2025
Table 5.18 Chinese IBD Drug Market Forecast ($m), 2014-2025
Table 6.1 Selected IL Inhibitors in Clinical Development, 2014
Table 6.2 Selected CAM Inhibitors in Clinical Development, 2014
Table 6.3 Selected TNF-alpha Inhibitors in Clinical Development, 2014
Table 6.4 Selected Stem Cell Therapies in Clinical Development, 2014
Table 6.5 Selected JAK Inhibitors in Clinical Development, 2014
Table 6.6 Selected Toll-like Receptor Agonist in Clinical Development, 2014
Table 6.7 Selected Other Classes in Clinical Development, 2014
Table 7.1 Strengths, Weaknesses, Opportunities and Threats in the IBD Drug Market, 2015
Table 7.2 Social, Technological, Economic and Political Forces on the IBD Drug Market, 2015
Table 8.1 Top 4 Companies for IBD Drugs: Revenues ($m) and Market Shares (%), 2013
Table 8.2 AbbVie Revenues ($m) and Market Share (%), 2013
Table 8.3 Janssen Revenues ($m) and Market Share (%), 2013
Table 8.4 Actavis Revenues ($m) and Market Share (%), 2013
Table 8.5 Shire Revenues ($m) and Market Share (%), 2013
Table 10.1 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Share (%) by Product Category, 2013, 2019, 2025
Table 10.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Region, 2013, 2019, 2025
Table 10.3 Summary of IBD Market Drivers and Restraints, 2014-2025

List of Figures
Figure 1.1 Inflammatory Bowel Disease Market Segmentation, 2014
Figure 3.1 World IBD Drugs Market Shares by Product Type (%), 2013
Figure 3.2 Global IBD Drug Market Forecast ($m), 2014-2025
Figure 3.3 World IBD Drugs Market Shares by Product Type (%), 2025
Figure 3.4 Global Biologics Forecast for IBD Market ($m), 2014-2025
Figure 3.5 Global Aminosalicylates Forecast for IBD Market ($m), 2014-2025
Figure 3.6 Global Antibiotics Forecast for IBD Market ($m), 2014-2025
Figure 3.7 Global Corticosteroids Forecast for IBD Market ($m), 2014-2025
Figure 3.8 Global Immunomodulators Forecast for IBD Market ($m), 2014-2025
Figure 4.1 World Humira Revenue Forecast ($m), 2014-2025
Figure 4.2 World Remicade Forecast ($m), 2014-2025
Figure 4.3 World Asacol Forecast ($m), 2014-2025
Figure 4.4 World Pentasa Forecast ($m), 2014-2025
Figure 4.5 World Lialda Forecast ($m), 2014-2025
Figure 4.6 World Tysabri Forecast ($m), 2014-2025
Figure 4.7 World Xifaxan Forecast ($m), 2014-2025
Figure 4.8 World Cimzia Forecast ($m), 2014-2025
Figure 4.9 World Entocort Forecast ($m), 2014-2025
Figure 4.10 World Neoral Forecast ($m), 2014-2025
Figure 4.11 World Medrol Forecast ($m), 2014-2025
Figure 4.12 World Canasa Forecast ($m), 2014-2025
Figure 4.13 World Apriso Forecast ($m), 2014-2025
Figure 4.14 World Azulfidine Forecast ($m), 2014-2025
Figure 4.15 World Entyvio Forecast ($m), 2014-2025
Figure 4.16 World Simponi Forecast ($m), 2014-2025
Figure 4.17 World Uceris Forecast ($m), 2014-2025
Figure 5.1 Global IBD Drug Market by Leading Country (%), 2013
Figure 5.2 Global IBD Drug Market by Leading Country (%), 2025
Figure 5.3 US IBD Drug Market Forecast ($m), 2014-2025
Figure 5.4 Japanese IBD Drug Market Forecast ($m), 2014-2025
Figure 5.5 EU5 IBD Drug Market Forecasts ($m), 2014-2025
Figure 5.6 German IBD Drug Market Forecast ($m), 2014-2025
Figure 5.7 French IBD Drug Market Forecast ($m), 2014-2025
Figure 5.8 UK IBD Drug Market Forecast ($m), 2014-2025
Figure 5.9 Spanish IBD Drug Market Forecast ($m), 2014-2025
Figure 5.10 Italian IBD Drug Market Forecast ($m), 2014-2025
Figure 5.11 BRIC IBD Drug Market Forecasts ($m), 2014-2025
Figure 5.12 Brazilian IBD Drug Market Forecast ($m), 2014-2025
Figure 5.13 Russian IBD Drug Market Forecast ($m), 2014-2025
Figure 5.14 Indian IBD Drug Market Forecast ($m), 2014-2025
Figure 5.15 Chinese IBD Drug Market Forecast ($m), 2014-2025
Figure 8.1 Top Producers of IBD Drugs: Market Shares (%), 2013

★調査レポート[世界の炎症性腸疾患(IBD)治療薬市場] ( Inflammatory Bowel Diseases (IBD): World Drug Industry and Market 2015-2025 / VGAIN4120208) 販売に関する免責事項
[世界の炎症性腸疾患(IBD)治療薬市場] ( Inflammatory Bowel Diseases (IBD): World Drug Industry and Market 2015-2025 / VGAIN4120208) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆